Invest now
Marksans Pharma share price
Balanced risk
- ₹267.00(-3.10%)July 17, 2026 15:29:54 PM IST
- NSE
- BSE
- Vol : 1.54 M (NSE + BSE)Last 20 day avg : 2.36 M
Marksans Pharma is trading -3.10% lower at Rs 267.00 as compared to its last closing price. Marksans Pharma has been trading in the price range of 275.10 & 264.10. Marksans Pharma has given 52.73% in this year & -0.70% in the last 5 days. Marksans Pharma has TTM P/E ratio 17.00 as compared to the sector P/E of 25.09.There are 2 analysts who have initiated coverage on Marksans Pharma. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 148.13 Crores in its last quarter.Listed peers of Marksans Pharma include Sun Pharmaceutical Industries (-0.87%), Divi's Laboratories (-0.84%), Torrent Pharmaceuticals (-4.72%).The Mutual Fund holding in Marksans Pharma was at 4.66% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Marksans Pharma was at 16.76% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 18 Jul 2026, 09:20 PM IST
- BetaHigh volatility1.51Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.11The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.33Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation2.32The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Marksans Pharma News
Marksans Pharma Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,933.10 | -0.87 | 4,63,804.52 | 38.74 | 5.6 | - | - |
| Divi's Laboratories | 7,258.05 | -0.84 | 1,92,678.42 | 74.01 | 11.59 | - | - |
| Torrent Pharmaceuticals | 4,766.60 | -4.72 | 1,61,373.73 | 76.16 | 20.12 | - | - |
| Cipla | 1,418.40 | -0.77 | 1,14,551.98 | 27.78 | 3.35 | - | - |
| Zydus Lifesciences | 1,142.75 | -0.93 | 1,13,894.32 | 21.38 | 4.28 | - | - |
Mutual Fund Ownership
View allMarksans Pharma Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-26 | Audited Results & Final Dividend |
| 2026-02-05 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-12 | Quarterly Results |
| 2025-05-19 | Audited Results & Final Dividend |
About the company Marksans Pharma
- IndustryBiotechnology & Drugs
- ISININE750C01026
- BSE Code524404
- NSE CodeMARKSANS
Marksans Pharma Limited is an India-based company, which is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates under single business segment, namely Pharmaceuticals. It operates two manufacturing facilities in Goa and maintains two research and development centers, located in Goa and in Navi Mumbai. Its product portfolio spreads various therapeutic segments of the cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products include pain management, upper respiratory, digestive health, vitamins, minerals and supplements (VMS) and skin care products. Its prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic.
Marksans Pharma Share Price FAQs
Marksans Pharma is trading at 267.00 as on Fri Jul 17 2026 09:59:54. This is -3.10% lower as compared to its previous closing price of 275.55.
The market capitalization of Marksans Pharma is 12146.56 Cr as on Fri Jul 17 2026 09:59:54.
The average broker rating on Marksans Pharma is Strong Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Marksans Pharma is 281.40 whereas the 52 wk low is 156.00
Marksans Pharma can be analyzed on the following key metrics -
- TTM P/E: 17.00
- Sector P/E: 25.09
- Dividend Yield: 0.33%
- D/E ratio: 0.11
Marksans Pharma reported a net profit of 417.90 Cr in 2026.
The Mutual Fund Shareholding was 4.66% at the end of 31 Mar 2026.
Quick Links
EQUITY QUICK LINKS
Marksans Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.